Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria
about
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administrationReduced susceptibility of Plasmodium falciparum to artesunate in southern MyanmarPharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria.Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC.Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria.Artemisinins.Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malariaProtein binding and alpha : beta anomer ratio of dihydroartemisinin in vivoPopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro.The antiviral activities of artemisinin and artesunate.Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients.CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam.The chemotherapy of rodent malaria. LX. The importance of formulation in evaluating the blood schizontocidal activity of some endoperoxide antimalarials.Synthesis of lipid derivatives of pyrrole polyamide and their biological activity.Synthesis and biological activity of fatty acid derivatives of quinine.Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin.Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity.
P2860
Q21034080-631BA5E3-8A5C-42BC-B345-2AEF99CE4707Q28487881-01849673-57C6-40EA-A356-C53C5452F007Q33958541-6ADFCE10-E2FB-4122-9DE7-344D11CAFD3BQ34106127-247D3BE6-3B53-4D56-BFEE-F87C24885249Q34299078-25E84B05-8413-4495-BBEB-1EDF126887ACQ34669043-C53F6004-09CC-46A3-8485-9158E400D169Q34993096-51F042F8-071F-44D4-8C6A-70A4718DFDBCQ35521094-F4C5F0B7-F649-471B-A23F-4DE2040799B9Q35607781-96832B65-31AA-4CB0-B504-3968240C4CB9Q35804378-529A0E8B-6F48-4741-821B-7305748AAF6BQ35826018-3B14914A-7424-4ED8-8264-E90526F372D8Q35867343-58CF49C1-699D-472D-9851-B5643116037CQ36125445-E6B09BF5-FBF0-49EE-BF49-363E68DA8DE6Q36573154-304D0240-053C-4F7B-8416-C920DCC66528Q37144854-5DB50DA0-C313-47CD-8602-9CC19F7F53BDQ37242654-E2A51762-F972-4CB0-B8CE-43CB9EDF4F77Q37962462-C4E89B1C-7100-4AE9-BADE-1F0F2E1EED70Q39022874-88F10252-CCC4-46BA-B346-FA72F071BF04Q39351654-C4E8FBDD-64F7-4FAB-8023-59A13F2DDDB9Q40147507-0B070ACC-8F41-4584-9D3F-C499C45DE52DQ40347940-790F5115-051A-48BB-9526-84FACE716BC7Q41040998-3988E25F-5BF5-4554-96E3-8C99F759E692Q41856813-9C38DF5D-E771-415E-A85C-68547FF0064CQ44242195-93E6EC5D-5DC8-4E0D-8F82-69093FDBF0BDQ46405195-519003CF-53A1-41DB-AA1F-F4EF8D359A5AQ53397034-11D11A13-ED1C-4627-928F-F71DF829E067
P2860
Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Oral bioavailability of dihydr ...... tients with falciparum malaria
@ast
Oral bioavailability of dihydr ...... tients with falciparum malaria
@en
Oral bioavailability of dihydr ...... tients with falciparum malaria
@nl
type
label
Oral bioavailability of dihydr ...... tients with falciparum malaria
@ast
Oral bioavailability of dihydr ...... tients with falciparum malaria
@en
Oral bioavailability of dihydr ...... tients with falciparum malaria
@nl
prefLabel
Oral bioavailability of dihydr ...... tients with falciparum malaria
@ast
Oral bioavailability of dihydr ...... tients with falciparum malaria
@en
Oral bioavailability of dihydr ...... tients with falciparum malaria
@nl
P2093
P2860
P1476
Oral bioavailability of dihydr ...... tients with falciparum malaria
@en
P2093
H L Phuöng
S M Powell
V D Phuong
P2860
P356
10.1046/J.1365-2125.2001.01395.X
P407
P577
2001-06-01T00:00:00Z